Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Heather Graham

Nurse Practitioner, Family Dover, DE Nurse Practitioner

NPI 1326714189 CMS profile 11073865

655 S Bay Rd, Ste 3D, Dover, DE 19901

Open in the dashboard

General payments

$6,312

293 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Graham of Dover, DE is reported in the CMS Open Payments database as having received $6,312 across 293 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,742 78
2024 General $1,508 81
2023 General $990 63
2022 General $886 64
2021 General $187 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Graham
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Heather Graham were reported at $2,742. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Heather Graham Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $187 $124 $35–$379 $132
2022 $886 $141 $44–$430 $149
2023 $990 $154 $49–$476 $160
2024 $1,508 $165 $51–$504 $164
2025 $2,742 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $2,195 49 payments
  2. Averitas Pharma Inc. $1,100 56 payments
  3. Abbott Laboratories $575 34 payments
  4. Scilex Pharmaceuticals Inc. $351 20 payments
  5. AbbVie, Inc. $299 14 payments
  6. Pfizer Inc. $270 26 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $216 22 payments
  8. Collegium Pharmaceutical, Inc. $166 9 payments
  9. IBSA Pharma Inc. $164 7 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $140 13 payments
  11. Other $838 43 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,927 284 payments
  2. Travel and Lodging $1,339 8 payments
  3. Education $45 1 payment
Products named General payments · program years 2021–2025
  1. INTELLIS ADAPTIVESTIM $1,938 31 payments
  2. Qutenza $1,202 63 payments
  3. ZTLido $351 20 payments
  4. NURTEC ODT Pain $270 26 payments
  5. PROCLAIM $233 13 payments
  6. NURTEC ODT Primary Care $216 22 payments
  7. Licart $164 7 payments
  8. Tirosint $164 7 payments
  9. ZAVZPRET $161 13 payments
  10. RELISTOR $152 14 payments
  11. Other $2,348 143 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

6,347

Median for Nurse Practitioner: 389

Drug cost

$387,384

Median for Nurse Practitioner: $21,885

Branded share of claims

33.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 140 $100,543
Movantik Naloxegol Oxalate Brand 81 $30,807
Oxycontin Oxycodone Hcl Brand 60 $28,690
Nurtec Odt Rimegepant Sulfate Brand 14 $26,441
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 787 $25,865
Belbuca Buprenorphine Hcl Brand 29 $21,023
Diclofenac Sodium Generic 472 $20,540
Lidocaine Generic 122 $14,750
Gabapentin Generic 702 $14,440
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 502 $12,015

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$398,904

Of which drugs: $155,988

Medicare patients

337

Average age 69

Services billed

61,306

208 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 41%
Depression 35%
Chronic kidney disease 32%
Ischemic heart disease 31%
COPD 27%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Capsaicin 8% patch, per square centimeter J7336 Office 22 55,440 $143,895
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 25 232 $177

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $491
$491 — 55,440
ZTLido
  • Scilex Pharmaceuticals Inc. $155
$155 13 —
Hizentra
  • CSL Behring $62
$62 — —
Tirosint
  • IBSA Pharma Inc. $54
$54 — —
Licart
  • IBSA Pharma Inc. $54
$54 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

293 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record